A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.

@article{Yoshikawa1999ACT,
  title={A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. The Japanese Pediatric IgA Nephropathy Treatment Study Group.},
  author={N. Yoshikawa and Hiroshi Ito and Tatsuo Sakai and Yasuo Takekoshi and Masataka Honda and Midori Awazu and Katsumi Ito and Kikuo Iitaka and Yasushi Koitabashi and Kazuhiro Yamaoka and Katsuhiro Nakagawa and H. Richard Nakamura and Shigeo Matsuyama and Yoshihiko Seino and Nobuaki Takeda and Shinzaburou Hattori and Makoto Ninomiya},
  journal={Journal of the American Society of Nephrology : JASN},
  year={1999},
  volume={10 1},
  pages={101-9}
}
The most appropriate treatment for patients with IgA nephropathy is controversial. Treatment with prednisolone, azathioprine, heparin-warfarin, and dipyridamole early in the course of disease may prevent immunologic renal injury in children with severe IgA nephropathy. To determine whether similar results can be obtained with a combination of just heparin-warfarin and dipyridamole, the effects of such treatment were compared to those of treatment with prednisolone, azathioprine, heparin… CONTINUE READING